ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
Chen XJ, Tong ZC, Kang X, Wang ZC, Huang GL, Yang TM, Dong L · European review for medical and pharmacological sciences
Sarcoma subtypes
Abstract
OBJECTIVE: The association between excision repair cross-complementation (ERCC) gene family (ERCC1 and ERCC2) and osteosarcoma risk was controversial. The aim of this study was to evaluate the association between ERCC1 or ERCC2 and osteosarcoma risk by systematic meta-analysis.
MATERIALS AND METHODS: Relative studies were retrieved from electronic databases without language restriction. The last search was updated on March 2017. Quality assessment was analyzed by the Newcastle-Ottawa Scale (NOS) score, which was recommended by the Agency for Healthcare Research and Quality (AHRQ). Meta-analysis was conducted by R language package (R 3.12).
RESULTS: This meta-analysis was performed based on 4 case-control studies that included 1208 cases and 2448 controls. The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
CONCLUSIONS: The ERCC2 rs1799793 polymorphism is related to the high risk of osteosarcoma development.
Shown exactly as published on PubMed. Your oncologist is the right person to judge whether these findings apply to your situation.
Publication type
Source: PubMed, PMID 30402838. Always confirm details with the original publication or your oncologist.